Performance Evaluation and Clinical Associations of Immunoassays That Detect Antibodies to Negatively Charged Phospholipids Other Than Cardiolipin

Amaris Castanon, Grant Pierre, Rohan Willis, E. Nigel Harris, Elizabeth Papalardo, Zurina Romay-Penabad, Alvaro Schleh, Praveen Jajoria, Monica Smikle, Karel Deceulaer, Anne Tebo, Troy Jaskowski, Marta M. Guerra, D. Ware Branch, Jane E. Salmon, Michelle Petri, Emilio Gonzalez

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Objectives: We evaluate the performance characteristics of antiphosphatidylserine (anti-PS), antiphosphatidylinositol (anti-PI), and antiphospholipid mixture (APhL) enzyme-linked immunosorbent assays (ELISAs) compared with anticardiolipin (aCL) and anti-β2 glycoprotein I (anti-β2GPI) in a large group of patients with antiphospholipid (aPL)-related diseases. Methods: Serum samples from 548 patients from the Hopkins and Jamaican systemic lupus erythematosus cohorts, the PROMISSE cohort, and the Antiphospholipid Standardization Laboratory were examined for immunoglobulin G (IgG)/immunoglobulin M (IgM) positivity in aCL, anti-β2GPI, anti-PS, anti-PI, and APhL ELISA assays. Results: All IgG assays were associated with one or more thrombotic and/or obstetric manifestations, with an increased risk associated with higher antibody titers. Analytical performance was similar among assays, but IgG assays performed better than IgM counterparts. Conclusions: Increasing titers of APhL, anti-PS, and anti-PI antibodies could indicate an increased risk of thrombotic and/or obstetric aPL-related manifestations. These assays may be promising biomarkers for particular APS manifestations.

Original languageEnglish (US)
Pages (from-to)401-411
Number of pages11
JournalAmerican Journal of Clinical Pathology
Volume149
Issue number5
DOIs
StatePublished - Mar 29 2018

Fingerprint

Cardiolipins
Immunoassay
Phospholipids
Immunoglobulin G
Obstetrics
Immunoglobulin M
Antibodies
Glycoproteins
Enzyme-Linked Immunosorbent Assay
Systemic Lupus Erythematosus
Biomarkers
Serum

Keywords

  • Anticardiolipin
  • Antiphosphatidylinositol
  • Antiphosphatidylserine
  • Antiphospholipid
  • APhL
  • Assay
  • Noncriteria

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Performance Evaluation and Clinical Associations of Immunoassays That Detect Antibodies to Negatively Charged Phospholipids Other Than Cardiolipin. / Castanon, Amaris; Pierre, Grant; Willis, Rohan; Nigel Harris, E.; Papalardo, Elizabeth; Romay-Penabad, Zurina; Schleh, Alvaro; Jajoria, Praveen; Smikle, Monica; Deceulaer, Karel; Tebo, Anne; Jaskowski, Troy; Guerra, Marta M.; Ware Branch, D.; Salmon, Jane E.; Petri, Michelle; Gonzalez, Emilio.

In: American Journal of Clinical Pathology, Vol. 149, No. 5, 29.03.2018, p. 401-411.

Research output: Contribution to journalArticle

Castanon, A, Pierre, G, Willis, R, Nigel Harris, E, Papalardo, E, Romay-Penabad, Z, Schleh, A, Jajoria, P, Smikle, M, Deceulaer, K, Tebo, A, Jaskowski, T, Guerra, MM, Ware Branch, D, Salmon, JE, Petri, M & Gonzalez, E 2018, 'Performance Evaluation and Clinical Associations of Immunoassays That Detect Antibodies to Negatively Charged Phospholipids Other Than Cardiolipin', American Journal of Clinical Pathology, vol. 149, no. 5, pp. 401-411. https://doi.org/10.1093/ajcp/aqy003
Castanon, Amaris ; Pierre, Grant ; Willis, Rohan ; Nigel Harris, E. ; Papalardo, Elizabeth ; Romay-Penabad, Zurina ; Schleh, Alvaro ; Jajoria, Praveen ; Smikle, Monica ; Deceulaer, Karel ; Tebo, Anne ; Jaskowski, Troy ; Guerra, Marta M. ; Ware Branch, D. ; Salmon, Jane E. ; Petri, Michelle ; Gonzalez, Emilio. / Performance Evaluation and Clinical Associations of Immunoassays That Detect Antibodies to Negatively Charged Phospholipids Other Than Cardiolipin. In: American Journal of Clinical Pathology. 2018 ; Vol. 149, No. 5. pp. 401-411.
@article{56301b96682a425dbe1d0f2e9276b2a0,
title = "Performance Evaluation and Clinical Associations of Immunoassays That Detect Antibodies to Negatively Charged Phospholipids Other Than Cardiolipin",
abstract = "Objectives: We evaluate the performance characteristics of antiphosphatidylserine (anti-PS), antiphosphatidylinositol (anti-PI), and antiphospholipid mixture (APhL) enzyme-linked immunosorbent assays (ELISAs) compared with anticardiolipin (aCL) and anti-β2 glycoprotein I (anti-β2GPI) in a large group of patients with antiphospholipid (aPL)-related diseases. Methods: Serum samples from 548 patients from the Hopkins and Jamaican systemic lupus erythematosus cohorts, the PROMISSE cohort, and the Antiphospholipid Standardization Laboratory were examined for immunoglobulin G (IgG)/immunoglobulin M (IgM) positivity in aCL, anti-β2GPI, anti-PS, anti-PI, and APhL ELISA assays. Results: All IgG assays were associated with one or more thrombotic and/or obstetric manifestations, with an increased risk associated with higher antibody titers. Analytical performance was similar among assays, but IgG assays performed better than IgM counterparts. Conclusions: Increasing titers of APhL, anti-PS, and anti-PI antibodies could indicate an increased risk of thrombotic and/or obstetric aPL-related manifestations. These assays may be promising biomarkers for particular APS manifestations.",
keywords = "Anticardiolipin, Antiphosphatidylinositol, Antiphosphatidylserine, Antiphospholipid, APhL, Assay, Noncriteria",
author = "Amaris Castanon and Grant Pierre and Rohan Willis and {Nigel Harris}, E. and Elizabeth Papalardo and Zurina Romay-Penabad and Alvaro Schleh and Praveen Jajoria and Monica Smikle and Karel Deceulaer and Anne Tebo and Troy Jaskowski and Guerra, {Marta M.} and {Ware Branch}, D. and Salmon, {Jane E.} and Michelle Petri and Emilio Gonzalez",
year = "2018",
month = "3",
day = "29",
doi = "10.1093/ajcp/aqy003",
language = "English (US)",
volume = "149",
pages = "401--411",
journal = "American Journal of Clinical Pathology",
issn = "0002-9173",
publisher = "American Society of Clinical Pathologists",
number = "5",

}

TY - JOUR

T1 - Performance Evaluation and Clinical Associations of Immunoassays That Detect Antibodies to Negatively Charged Phospholipids Other Than Cardiolipin

AU - Castanon, Amaris

AU - Pierre, Grant

AU - Willis, Rohan

AU - Nigel Harris, E.

AU - Papalardo, Elizabeth

AU - Romay-Penabad, Zurina

AU - Schleh, Alvaro

AU - Jajoria, Praveen

AU - Smikle, Monica

AU - Deceulaer, Karel

AU - Tebo, Anne

AU - Jaskowski, Troy

AU - Guerra, Marta M.

AU - Ware Branch, D.

AU - Salmon, Jane E.

AU - Petri, Michelle

AU - Gonzalez, Emilio

PY - 2018/3/29

Y1 - 2018/3/29

N2 - Objectives: We evaluate the performance characteristics of antiphosphatidylserine (anti-PS), antiphosphatidylinositol (anti-PI), and antiphospholipid mixture (APhL) enzyme-linked immunosorbent assays (ELISAs) compared with anticardiolipin (aCL) and anti-β2 glycoprotein I (anti-β2GPI) in a large group of patients with antiphospholipid (aPL)-related diseases. Methods: Serum samples from 548 patients from the Hopkins and Jamaican systemic lupus erythematosus cohorts, the PROMISSE cohort, and the Antiphospholipid Standardization Laboratory were examined for immunoglobulin G (IgG)/immunoglobulin M (IgM) positivity in aCL, anti-β2GPI, anti-PS, anti-PI, and APhL ELISA assays. Results: All IgG assays were associated with one or more thrombotic and/or obstetric manifestations, with an increased risk associated with higher antibody titers. Analytical performance was similar among assays, but IgG assays performed better than IgM counterparts. Conclusions: Increasing titers of APhL, anti-PS, and anti-PI antibodies could indicate an increased risk of thrombotic and/or obstetric aPL-related manifestations. These assays may be promising biomarkers for particular APS manifestations.

AB - Objectives: We evaluate the performance characteristics of antiphosphatidylserine (anti-PS), antiphosphatidylinositol (anti-PI), and antiphospholipid mixture (APhL) enzyme-linked immunosorbent assays (ELISAs) compared with anticardiolipin (aCL) and anti-β2 glycoprotein I (anti-β2GPI) in a large group of patients with antiphospholipid (aPL)-related diseases. Methods: Serum samples from 548 patients from the Hopkins and Jamaican systemic lupus erythematosus cohorts, the PROMISSE cohort, and the Antiphospholipid Standardization Laboratory were examined for immunoglobulin G (IgG)/immunoglobulin M (IgM) positivity in aCL, anti-β2GPI, anti-PS, anti-PI, and APhL ELISA assays. Results: All IgG assays were associated with one or more thrombotic and/or obstetric manifestations, with an increased risk associated with higher antibody titers. Analytical performance was similar among assays, but IgG assays performed better than IgM counterparts. Conclusions: Increasing titers of APhL, anti-PS, and anti-PI antibodies could indicate an increased risk of thrombotic and/or obstetric aPL-related manifestations. These assays may be promising biomarkers for particular APS manifestations.

KW - Anticardiolipin

KW - Antiphosphatidylinositol

KW - Antiphosphatidylserine

KW - Antiphospholipid

KW - APhL

KW - Assay

KW - Noncriteria

UR - http://www.scopus.com/inward/record.url?scp=85045132273&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045132273&partnerID=8YFLogxK

U2 - 10.1093/ajcp/aqy003

DO - 10.1093/ajcp/aqy003

M3 - Article

C2 - 29547897

AN - SCOPUS:85045132273

VL - 149

SP - 401

EP - 411

JO - American Journal of Clinical Pathology

JF - American Journal of Clinical Pathology

SN - 0002-9173

IS - 5

ER -